Biochemical and Clinical Aspects of the Human Flavin-Containing Monooxygenase Form 3 (FMO3) Related to Trimethylaminuria
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Trimethylaminuria is a rare metabolic disorder that is associated with abnormal amounts of the dietary-derived trimethylamine. Excess unmetabolized trimethylamine in the urine, sweat and other body secretions confers a strong, foul body odor that can affect the individual's ability to work or engage in social activities. This review summarizes the biochemical aspects of the condition and the classification of the disorder into: 1) primary genetic form, 2) acquired form, 3) childhood forms, 4) transient form associated with menstruation, 5) precursor overload and 6) disease states. The genetic variability of the flavin-containing monooxygenase (form 3) that is responsible for detoxication and deodoration of trimethylamine is discussed and put in context with other variant forms of the flavin-containing monooxygenase (forms 1-5). The temporal-selective expression of flavin-containing monooxygenase forms 1 and 3 is discussed in terms of an explanation for childhood trimethylaminuria. Information as to whether variants of the flavin-containing monooxygenase form 3 contributes to hypertension and/or other diseases are presented. Discussion is provided outlining recent bioanalytical approaches to quantify urinary trimethylamine and trimethylamine N-oxide and plasma choline as well as data on self-reporting individuals tested for trimethylaminuria. Finally, trimethylaminuria treatment strategies and nutritional support are described including dietary sources of trimethylamine, vitamin supplementation and drug treatment and issues related to trimethylaminuria in pregnancy and lactation are discussed. The remarkable progress in the biochemical, genetic, clinical basis for understanding the trimethylaminuria condition is summarized and points to needs in the treatment of individuals suffering from trimethylaminuria.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“humans with genetic defects in FMO3 suffer from Fish Odor Syndrome due to the accumulation of TMA and its noxious odor”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Cashman et al., 2003
Citations
Cites
Physiology, biochemistry, and molecular biology of the skin
Goldsmith, L. A. (1991) · Oxford University Press eBooks · Cited by 448
Bad Breath—Research Perspectives
Rosenberg, M., & Doyle, R. J. (1995) · Journal of Dental Research · doi:10.1177/00220345950740051501 · Cited by 119
Trimethylamine and Foetor Hepaticus
Mitchell, S. C. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750026281 · Cited by 46
Self-citation
Cited by
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Wang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.055 · Cited by 1,317
“It is also well established that humans with genetic defects in FMO3 suffer from fish odor syndrome, due to the accumulation of TMA and its noxious odor (Cashman et al., 2003), reducing the appeal of FMO3 as a potential therapeutic target for inhibition.”
BackgroundRole of gut microbiota in atherosclerosis
Jonsson, A. L., & Bäckhed, F. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.183 · Cited by 644
Krueger, S. K., & Williams, D. E. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.01.001 · Cited by 567
“A number of allelic variants have been associated with the incidence and severity of TMAU in patients (Zhang et al., 1996, 2003; Cashman et al., 1997, 2000, 2001, 2003; Dolphin et al., 1997; Kang et al., 2000; Murphy et al., 2000; Forrest et al., 2001; Cashman, 2002; Cashman & Zhang, 2002; Park et…”
BackgroundHUMAN FLAVIN-CONTAINING MONOOXYGENASES
Cashman, J. R., & Zhang, J. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141043 · Cited by 333
Self-citation
Metadata
- Authors
- Cashman, J., Camp, K., Fakharzadeh, S., Fennessey, P., Hines, R., Mamer, O., Mitchell, S., Preti, G., Schlenk, D., & Smith, R.
- Affiliations
- Human BioMolecular Research Institute (US)
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-04-01
- Volume
- 4
- Issue
- 2
- Pages
- 151-170
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2138685029
- Cited by
- 110
- References
- 3
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 5 · 2016: 5 · 2015: 3 · 2014: 12 · 2013: 6 · 2012: 4
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 59618, R01DK059618)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Polyamine Metabolism and Applications
- Keywords
- trimethylaminuria, FMO3, trimethylamine, trimethylamine N-oxide, choline, hypertension, plasma choline, dietary management, vitamin supplementation, pregnancy and lactation, body odor
- MeSH terms
- Animals, Clinical Trials as Topic, Diet, Genotype, Humans, Hypertension, Liver, Metabolic Diseases, Metabolism, Inborn Errors, Methylamines, Odorants, Oxygenases, Polymorphism, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biochemical and Clinical Aspects of the Human Flavin-Containing Monooxygenase Form 3 (FMO3) Related to Trimethylaminuria. https://app.cochat.ai/papers/10.2174/1389200033489505
- The paper
- Cashman, J., Camp, K., Fakharzadeh, S., Fennessey, P., Hines, R., Mamer, O., Mitchell, S., Preti, G., Schlenk, D., & Smith, R. (2003). Biochemical and Clinical Aspects of the Human Flavin-Containing Monooxygenase Form 3 (FMO3) Related to Trimethylaminuria. Current Drug Metabolism. https://doi.org/10.2174/1389200033489505
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.